← Latest news 
Sun Pharma to buy Organon for 11.75 billion all cash deal
Economy
Published on 27 April 2026
The per share price marks a bold move
Sun Pharmaceutical Industries has agreed to acquire U.S. drugmaker Organon & Co in an all-cash transaction worth about $11.75 billion including debt. Sun will buy every outstanding Organon share for $14.00 each, giving it full ownership of a company known for women’s health, biosimilars, and established therapies.
- Sun Pharma will acquire Organon in an all-cash $11.75 billion deal
- Offer price is $14.00 per share for all outstanding shares
- Acquisition makes Sun the full owner of Organon
- Organon focuses on women’s health, biosimilars, and established medicines
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times